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a b s t r a c t
Vif is essential for HIV-1 replication in T cells and macrophages. Vif recruits a host ubiquitin ligase
complex to promote proteasomal degradation of the APOBEC3 restriction factors by poly-ubiquitination.
The cellular transcription cofactor CBFβ is required for Vif function by stabilizing the Vif protein and
promoting recruitment of a cellular Cullin5-RING ubiquitin ligase complex. Interaction between Vif and
CBFβ is a promising therapeutic target, but little is known about the interfacial residues. We now
demonstrate that Vif conserved residues E88/W89 are crucial for CBFβ binding. Substitution of E88/W89
to alanines impaired binding to CBFβ, degradation of APOBEC3, and virus infectivity in the presence of
APOBEC3 in single-cycle infection. In spreading infection, NL4-3 with Vif E88A/W89A mutation
replicated comparably to wild-type virus in permissive CEM-SS cells, but not in multiple APOBEC3
expressing non-permissive CEM cells. These results support a model in which HIV-1 Vif residues E88/
W89 may participate in binding CBFβ.
& 2013 Elsevier Inc. All rights reserved.
Introduction
HIV-1 Vif is one of six viral accessory proteins and it is essential
for the viral replication in T cells and macrophages (Gabuzda et al.,
1992, 1994). Vif recruits host proteins, cullin 5 (CUL5), RING-box
protein 2 (RBX2), elongin C (ELOC) and elongin B (ELOB), and forms a
ubiquitin ligase complex that promotes poly-ubiquitination and
proteasomal degradation of the APOBEC3 (A3) retrovirus restriction
factors (Jäger et al., 2011; Marin et al., 2003; Sheehy et al., 2003;
Shirakawa et al., 2006; Stopak et al., 2003; Yu et al., 2003). A3s are
DNA cytosine deaminases that convert cytosines to uracils in single-
stranded DNA (Chelico et al., 2006; Harris et al., 2003). In the absence
of the Vif protein, at least two A3 family members, A3F and A3G, are
efﬁciently incorporated into budding virions, where they deaminate
cytosines in newly reverse-transcribed minus-strand virus DNA in
target cells, leading to guanine to adenine hypermutation of the virus
genome (Harris et al., 2003; Hultquist et al., 2011b; Sheehy et al.,
2002; Zhang et al., 2003).
Amino acid sequences of HIV-1 Vif vary among viral strains,
but more than ten regions of residues are conserved (Dang et al.,
2010), and several conserved motifs have been shown to interact
with host proteins. The BC-box motif 144SLQYLA149 binds to
ELOC (Mehle et al., 2004; Yu et al., 2004), and the HCCH motif
108Hx5Cx17-18Cx3–5H139 binds to CUL5 (Luo et al., 2005; Mehle et al.,
2006). Furthermore, the N-terminal half of Vif contains distinct
regions involved in the Vif-A3 protein-protein interactions;
11WQxDRMR17 and 76ExxW79 motifs are involved in neutralization
of A3F (He et al., 2008; Russell and Pathak, 2007), whereas 40YRHHY44
motif is involved in neutralization of A3G (Russell and Pathak, 2007);
22KSLVK26 and 55VxIPLx4-5Lxφx2YWxL72 motifs were reported to be
involved in neutralization of both A3F and A3G (Chen et al., 2009;
Dang et al., 2009; He et al., 2008; Pery et al., 2009), although there
exists a report that K26 is required for neutralization of A3G, but not
of A3F (Albin et al., 2010).
Recently, the transcription factor core binding factor-β (CBFβ)
has been shown to be involved in the Vif ubiquitin ligase complex
(Jäger et al., 2011; Zhang et al., 2011), and critical for its function by
stabilizing the Vif protein in cells (Jäger et al., 2011), and enabling
the recruitment of CUL5 (Zhang et al., 2011). There are two isoforms
of CBFβ, and both isoforms stabilize Vif protein, enhance A3
degradation, and increase virion infectivity (Hultquist et al., 2011a).
Thus, the interaction between Vif and CBFβ is a promising
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therapeutic target, but little is known about the interfacial amino
acids. Hultquist et al. reported that surface F68 residue of CBFβ is
involved in binding and stabilizing Vif (Hultquist et al., 2012). Zhang
et al. reported that W21 and W38 residues of Vif are required for
binding to CBFβ by co-immunoprecipitation experiments (Zhang
et al., 2011; Kim et al., 2013). Furthermore, Kim et al. recently
suggested that L64 and I66 residues are involved in binding to CBFβ
by co-puriﬁcation in Escherichia coli (Kim et al., 2013).
Because a previous study indicated that a hydrophilic region
88EWRKKR93 is essential for Vif expression and HIV-1 replication
(Fujita et al., 2003), we hypothesized that conserved residues E88
and W89 in this region may be required for CBFβ binding. In this
study, we generated amino acid substitution mutants of these
residues as well as W21 and W38, and simultaneously analyzed
both binding to CBFβ and Vif-mediated degradation of A3F and
A3G. We show that the conserved residues E88 and W89 of HIV-1
Vif are directly involved in CBFβ binding and Vif-mediated
degradation of A3F and A3G.
Results
The conserved residue W89 of HIV-1 Vif is required
for the interaction with CBFβ
To test our hypothesis that conserved residues E88 and W89 may
be required for CBFβ binding, we generated nine Vif amino acid
substitution mutants, D14A/R15A, W21A, W38A, Y40A, Y69A, G84D,
E88A,W89A, and E88A/W89A (Fig. 1A). W21 andW38 were reported
to be involved in CBFβ binding (Zhang et al., 2011), D14 and R15 for
APOBEC3F binding (Russell and Pathak, 2007), Y40 for A3G binding
(Russell and Pathak, 2007), Y69 and G84 for both A3F and A3G
binding (Dang et al., 2010; Pery et al., 2009). All of these residues are
highly conserved, suggesting that they could be involved in CBFβ
binding region of Vif. We ﬁrst performed co-immunoprecipitation
experiments in 293T cells by over-expression of Vif with C-terminal
myc tag. Vif is a relatively unstable proteinwith a short half-life and it
is degraded by the cellular proteasome (Dussart et al., 2004; Fujita
et al., 2004; Mehle et al., 2004). Mouse double minute 2 homolog
(MDM2) is the E3 ubiquitin ligase which targets Vif for degradation
(Izumi et al., 2009). Because it has been reported that Vif degradation
is accelerated in the absence of CBFβ, and that treatment with the
proteasome inhibitor MG132 reverses this effect (Jäger et al., 2011),
we used MG132 to minimize proteasomal proteolysis of Vif in cell
culture and immunoprecipitation experiments. Although we trans-
fected with the same amount of plasmid DNA, expression levels of
E88A, W38A, D14/R15AA, Y40A, Y69A and G84D were comparable to
wild-type Vif, but those of W89A, E88/W89A and W21A mutants
were obviously impaired (Fig. S1, 2nd top panel). These modest
expression levels of these mutants can be simply explained by
misfolding, but an alternative explanation is due to loss of CBFβ
binding. The amounts of immunoprecipitated Vif protein showed a
smaller variation, compared to expression levels (Fig. S1, bottom
panel). More importantly, endogenous CBFβ co-precipitated with
wild-type Vif, D14A/R15A, Y40A, G84D, and E88A, but not with
W21A, W89A, or E88A/W89A (Fig. S1, 3rd top panel). W38A and
Y69A showed intermediate results (Fig. S1, lanes 7 and 10, 3rd top
panel). To exclude the possibility that low expression of W21A,
W89A and E88A/W89A mutants caused the low amount of co-
immunoprecipitated CBFβ, we compensated by increasing the
amount of transfected plasmid DNA, and performed an additional
round of co-immunoprecipitation experiments. Although expression
levels of W21A, W89A and E88A/W89A mutants were now higher
than wild-type Vif, endogenous CBFβ did not co-precipitate with
these mutants (Fig. 1B). We next examined whether CUL5 co-
precipitated with Vif mutants by immunoblotting with some of the
samples of Fig. 1B, because CBFβ binding has been reported to be
required for Vif to interact with CUL5 (Zhang et al., 2011). Endogen-
ous CUL5 appeared to co-precipitate with wild-type Vif, but not with
W21A, W38A, W89A, or E88A/W89A (Fig. 1C, 2nd bottom panel). All
Fig. 1. Vif substitution mutants and binding capacity to CBFβ. (A) Schematic of Vif conserved motifs and nine substitution mutants generated. The residues substituted are
indicated by bold lines. (B) Co-immunoprecipitation of endogenous CBFβ with Vif. Lysates of 293T cells transiently expressing myc-tagged Vif wild-type or mutant were
immunoprecipitated by anti-myc serum. Samples were analyzed by immunoblotting with anti-CBFβ and anti-myc sera. (C) Co-immunoprecipitation of endogenous CUL5
with Vif. Samples from (B) were also analyzed with anti-CUL5 serum. Panels for Vif were re-produced from (B).
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of these mutants of Vif bound to ELOB (Fig. S2), suggesting that they
are not entirely misfolded proteins, although previous reports
indicated that fragments of the Vif BC box is sufﬁcient for binding
to ELOB and ELOC (Bergeron et al., 2010; Wolfe et al., 2010).
Altogether, these results suggest that W89 is involved in CBFβ
binding, as well as W21 and W38.
The substitution of E88/W89 to alanines impairs Vif-mediated
degradation of both A3F and A3G proteins
To examine whether the loss of binding to CBFβ causes
impaired Vif-mediated degradation of A3 proteins, we next per-
formed a series of co-transfection and immunoblot experiments.
293T cells were co-transfected with expression vectors for A3G
with myc tag and Vif wild-type or mutant, and protein levels of
A3G were analyzed by immunoblotting. To obtain comparable
expression levels of each of the Vif mutants, we again adjusted the
amount of plasmid DNA transfected. Co-transfection of wild-type
Vif reduced APOBEC3G levels, but E88A/W89A, W21A or W38A did
not (Fig. 2A, lanes 1, 2 and 7–12). E88A or W89A alone reduced
A3G levels close to wild-type Vif (Fig. 2A, lanes 3–6). Because W21
and W38 are close to A3G binding residues of Vif, 40YRHHY44, the
loss of A3G degradation by W21A or W38A might be caused by
loss of A3G binding. To exclude this possibility, we next performed
co-transfection experiments with Vif and A3F expression vectors
and similar results were obtained (Fig. 2B). These results suggest
that the substitution of E88/W89 as well as W21 and W38 to
alanines leads to an impairment of Vif-mediated degradation of
both A3F and A3G due to the loss of binding to CBFβ, not to A3F
or A3G.
The substitution of E88/W89 to alanines impairs the ability of Vif
to counteract the restriction by both A3F and A3G
To examine the ability of Vif mutants to counteract the restric-
tion of HIV-1 by A3 proteins, we next performed single cycle
infection experiments using luciferase-reporter viruses. The Vif
mutations were introduced into pNL4-3 ΔEnv-Luc, and transfected
into 293T cells with co-transfection of VSV-G expression plasmid
in the presence or absence of co-transfection of A3G expression
plasmid. Virus-containing supernatant was harvested and infectiv-
ity was measured by challenging to fresh 293T cells and assaying
luciferase activity. Viruses with Vif mutations showed comparable
infectivity in the absence of A3G, as expected (Fig. 3A). In the
presence of A3G, virus with E88A mutation showed comparable
infectivity to wild-type, but virus with W21A, W38A or E88A/W89A
showed deeply impaired infectivity close to that of ΔVif (Fig. 3A).
Virus with W89A showed intermediate and obviously impaired
infectivity in the presence of A3G (Fig. 3A). We also performed
these assays with A3F instead of A3G, and obtained similar results
(Fig. 3B). These data indicate that E88/W89 residues as well as W21
and W38 are involved in Vif activity to counteract both A3F and
A3G, suggesting these residues are involved in CBFβ binding, not
A3F or A3G binding.
The substitution of E88/W89 to alanines impairs HIV-1 replication
in non-permissive CEM cells
Finally, we performed spreading infection experiments in both
permissive CEM-SS and multiple A3-expressing CEM cells. We
introduced Vif mutations into NL4-3, a replication-competent
Fig. 2. Degradation of A3F and A3G by Vif. (A) Degradation of A3G. HEK293T cells
were co-transfected with expression vectors for myc-tagged A3G and Vif wild-type
or mutant, and protein levels of A3G and Vif were analyzed by immunoblotting
with anti-myc serum and anti-tubulin antibody for loading control. The same
amount of the A3G expression plasmid was transfected in each sample.
(B) Degradation of A3F. Similar experiments to (A), but an A3F expression vector
was used instead of that of A3G.
Fig. 3. Single-cycle infection experiments with VSV-G pseudo-typed viruses with vif mutations. (A) Counteracting abilities of Vif mutants against the restriction by A3G.
293T cells were transfected with pNL43/ΔEnv-Luc with vif mutation, together with pVSV-G, in the presence or absence of pcDNA3/HA-A3G. pNL43/ΔEnv-Luc without vif
mutation and pNL43/ΔEnvΔvif-Luc were also used for control. Virus-containing supernatant was challenged to fresh 293T cells and infectivity was determined by
luminometer. Values were normalized to that of the virus without vif mutation in the absence of A3G. Average and standard errors of 3 independent experiments are shown.
Levels of A3G in cells and virions and Vif in cells were also analyzed by immunoblotting. (B) Counteracting abilities of Vif mutants against the restriction by A3F. Similar
experiments to (A), but pcDNA3/HA-A3F was used instead of the A3G plasmid.
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molecular clone, and analyzed whether the substitution mutation
impairs virus replication with spreading infection assays. Virus with
E88A or W89A showed comparable replication proﬁles to wild-type
virus in both CEM-SS and CEM cells. Virus with ΔVif, E88A/W89A,
W21A, or W38A showed indistinguishable replication proﬁles to
wild type in CEM-SS cells, as expected, whereas in CEM cells,
showed deeply impaired replication proﬁles (Fig. 4). These results
indicate that the residues E88/W89 as well as W21 and W38 are
critical for Vif to counteract multiple A3s, suggesting that these
residues are directly involved in CBFβ binding.
Discussion
In this study, we report that HIV-1 Vif residues E88 and W89
are involved in CBFβ binding, therefore in rendering Vif capable
of stable expression and inducing ubiquitination of both A3F and
A3G proteins. Fujita et al. reported that deletion or substitution
of these residues impairs steady-state levels of Vif protein and
virus replication in nonpermissive H9 cells and monocyte-derived
macrophages (Fujita et al., 2003). We conﬁrmed lower expression
levels of substitution mutants using both Vif expression vectors
and molecular clones of HIV-1. We also conﬁrmed inefﬁcient
replication of virus with the mutation using another nonpermis-
sive T cell line, CEM cells. These observations may be all explained
by the loss of CBFβ binding.
Our results suggest that the single amino acid substitution
mutant W89A does not bind to CBFβ, however this mutant is
capable of degradation of A3F and A3G, and supporting replication
of the virus in non-permissive CEM cells. This modest conﬂict
may be due to the differences in experimental settings;
co-immunoprecipitation experiments test the interactions in vitro
in complex total cell lysates, and degradation experiments and
infectivity experiments test Vif functionality in living cells.
Zhang et al. reported that Vif residues W21 and W38 are
involved in binding to CBFβ, but functional correlation of these
residues was not described (Zhang et al., 2011). We conﬁrmed that
these residues are critical for CBFβ binding, and further
demonstrated that these residues are critical for degradation of
both A3F and A3G, counteracting restriction by both A3F and A3G,
and replication in nonpermissive, multiple A3-expressing cells.
Jäger et al. reported that CBFβ functions to up-regulate steady-
state level of Vif protein by using cells with CBFβ knock-down
(Jäger et al., 2011). We observed that the levels of Vif mutants that
do not bind to CBFβ were obviously lower than that of wild-type
Vif. Our observations conﬁrmed and support the Jäger's report by
the experiments with different settings.
Several E3 ligases including CUL5, NEDD4, and AIP4, have been
reported to induce Vif ubiquitination, although biological implica-
tions have not been well deﬁned (Dussart et al., 2004; Mehle et al.,
2004). We previously reported that MDM2 targets for Vif as an E3
ligase to induce its ubiquitination and proteasomal degradation,
and that the N-terminal region of Vif (residues 4–22) is required
for MDM2 binding (Izumi et al., 2009). Because one of the CBFβ
binding residues of Vif, W21, is located close to MDM2 binding
region, the loss of CBFβ binding might facilitate ubiquitination
and degradation of Vif by MDM2. Further investigations will be
required to test this possibility.
We provide here the evidence indicating that residues W21,
W38, E88 and W89 of HIV-1 Vif are involved in binding surface to
CBFβ. Further studies on the Vif-CBFβ co-crystal structure will be
the key to understanding Vif-CBFβ interaction surfaces, and to
pharmaceutical applications of these pieces of information for
patients with HIV-1 infection.
Materials and methods
Plasmid construction
C-terminally myc-tagged Vif expression plasmid, pDON-Vif-myc,
was generated by amplifying NL4-3 vif coding sequence with
primers ATA GGA TCC ATG GAA AAC AGA TG G CAG GTG GCA GGT
GAT G and CGC GTC GAC CTA CAG ATC CTC TTC AGA GAT GAG TTT
CTG CTC GTA GTG TCC ATT CAT TGT ATG GCT CCC, and inserting it
into pDON-AI (Takara) at BamH I/Sal I sites. Expression plasmids for
Fig. 4. Spreading infection of NL4-3 with vif mutations. The viruses were produced in 293T cells and challenged to permissive CEM-SS cells and nonpermissive CEM cells at
MOI of 0.005. Culture supernatant was collected periodically and p24 levels were determined by ELISA.
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Vif mutants were generated by a PCR-based method with properly
mutated primers. HA-tagged expression plasmids for A3F and A3G
were previously described (Shirakawa et al., 2006). N-terminally
myc-tagged expression plasmids for A3F, pcDNA3-myc-A3F, was
generated by amplifying coding sequences of human A3F with
primers CTA GCT AGC ATG GAG CAG AAA CTC ATC TCT GAA GAG
GAT CTG ATG AAG CCT CAC TTC AGA AAC ACA GTG G and GGG GTA
CCT CAC TCG AGA ATC TCC TGC AGC TTG CTG, and inserting it into
pcDNA3.1 (Invitrogen) at Nhe I/Kpn I sites. C-terminally myc-tagged
expression plasmids for A3G, pcDNA3-A3G-myc, was generated by
amplifying coding sequences of human A3G with primers ATA CTC
GAG AAT GAA GCC TAC TTC AGA AAC ACA GTG and GGG GTA CCC
TAC AGA TCC TCT TCA GAG ATG AGT TTC TGC TCG CAG TTT TCC TGA
TTC TGG AGA ATG GC, and inserting it into pcDNA3.1 (Invitrogen) at
Xho I/Kpn I sites. The luciferase-reporter HIV-1 plasmids for single-
cycle infection, pNL43/ΔEnv-Luc and pNL43/ΔEnvΔvif-Luc were
previously described (Shindo et al., 2003). Mutations in vif region of
pNL43/ΔEnv-Luc and pNL4-3 were introduced by a PCR-based
method using internal restriction sites, MSC I at position 4553,
and EcoR I at position 5743.
Cell culture and transfection
293T cells were maintained in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% fetal bovine serum (FBS) and
penicillin, streptomycin and glutamine (PSG). CEM and CEM-SS cells
were maintained in RPMI1640 medium supplemented with 10% FBS
and PSG. 293T cells on 6-well plates were transfected with about
1 μg of plasmid DNA in total using X-tremegene HP DNA transfec-
tion reagent (Roche) according to manufacturer's instruction.
Immunoblotting
Primary antibodies for immunoblotting against Vif, A3G and
p24Gag were obtained from the NIH AIDS Research and Reference
Reagent Program. Rabbit anti-CBFβ serum and mouse anti-Cul5
and anti-HA antibodies were purchased from Santa Cruz. Rabbit
anti-myc serum was purchased from Sigma. Mouse anti-tubulin
antibody was purchased from Covance. HRP-conjugated secondary
antibodies against mouse and rabbit were purchased from GE
Healthcare. We used a standard chemiluminescence protocol for
immunoblotting with PVDF membrane (Millipore).
Immunoprecipitation
For co-immunoprecipitation to test interaction of Vif mutant to
CBFβ, 293T cells were transfected with pDON-Vif-myc or its deriva-
tive mutant, treated with MG132 at concentration of 2.5 μM for 16 h,
and lysed with co-IP buffer (25 mM HEPES, pH 7.4, 150 mM NaCl,
0.1% Triton X-100, 1 mM EDTA, 1mM MgCl2) supplemented with
protease inhibitor cocktail (Nacalai) and MG132. After centrifugation
at 20,000 g for 10 min, supernatant was mixed with 2 μg anti-myc
rabbit serum (Sigma) for 1 h, and then mixed with 20 μl protein A
sepharose (Pharmacia) for 1 h. Beads were washed with co-IP buffer
3 times, and bound protein was eluted with 1 x SDS sample buffer.
Samples were analyzed by immunoblotting as described above.
Single-cycle infection
Luciferase encoding HIV-1 particles were produced by transiently
transfecting 293T cells at 50% conﬂuency using 0.8 μg pNL43/ΔEnv-
Luc or derivative mutant, 0.2 μg pVSV-G and 0.02 μg pcDNA3/HA-
A3F, pcDNA3/HA-A3G, or empty vector. After 48 h, virus-containing
supernatants were harvested through PVDF ﬁlter with 0.45 μm
pores (Millipore), and challenged to fresh 293T cells. After 48 h,
cells were lysed with Passive lysis buffer (Promega) and luciferase
activity was determined by luminometer (2030 Arvo X, Perkin
Elmer) using Luciferase Assay System (Promega). Sample prepara-
tion of producer cells and virus for immunoblotting was performed
as described (Haché et al., 2008).
Spreading infection
293T cells were transfected with NL4-3 molecular clone or
derivative mutant, and virus-containing supernatant was har-
vested through PVDF ﬁlters with 0.45 μm pores (Millipore) after
2-day incubation. CEM-SS and CEM cells were inoculated with the
supernatant at MOI of 0.005. The culture supernatants were
harvested periodically, and analyzed for p24 by an HIV-1 p24
antigen ELISA kit (Zeptometrix).
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